MicroStructure Imaging, Inc.

New York, NY · Medtech · Private

Software-as-a-service platform using random matrix theory and principal component analysis to enhance signal-to-noise ratio in MRI brain imaging reconstruction

Claim this profile

Follows are private to you and power your alerts

Updated

Sector
Medtech
Headquarters
New York, NY
Latest Form D
$590K, Aug 2023
Total capital
$1.8M
Federal grants
$1.2M
4 awards · 2021–2025
Rank in peer group#43 of 53
Private capital raised
$590K
1 Form D · last Aug 2023
38 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

20212022202320242025FEDERAL ↑EQUITY ↓Cumulative $1.8M$455K$55K$354K$365K1st Form D$590K
20212022202320242025FEDERAL ↑EQUITY ↓Cumulative $1.8M$455K$55K$354K$365K1st Form D$590K

Latest events

  • Federal grantHealth and Human S · Phase I · Reporting Quantitative Microstructural MRI Metrics to Stage and Monitor Multiple Sclerosis$365K
  • Federal grantHealth and Human S · Phase I · Reporting Quantitative Microstructural MRI Metrics to Stage and Monitor Multiple Sclerosis$354K
  • Private capital raisedForm D · SEC · 1st filing$590K
  • Federal grantHealth and Human S · Phase I · Non-invasive neurosurgical planning with Random Matrix Theory MRI$55K
  • Federal grantHealth and Human S · Phase I · Non-invasive neurosurgical planning with Random Matrix Theory MRI$455K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Federal first

23months

from MicroStructure Imaging, Inc.’s first federal award to its first private round.

First federal award · Sep 2021
Health and Human S · $455K
First Form D · Aug 2023
$590K · 1st Form D
Awards before first raise
2 awards

An association in public records, not a cause or a prediction.

Standing among 53 peers

Line = median

Medtech · Software

  • Federal grantsBelow median

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • Benjamin Ades-aronExecutive Officer, DirectorNamed in SEC Form D filings
  • Gregory Lemberskiy LemberskiyExecutive Officer, DirectorNamed in SEC Form D filings

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

  • CELL IDX, INC.Similar federal contract value in Medtech · null in contracts
  • PROTEAS BIOANALYTICS INC.Similar federal contract value in Medtech · null in contracts
  • GATEWAY BIOTECHNOLOGY, INC.Similar federal contract value in Medtech · null in contracts
  • ENDOTHEIA INCSimilar federal contract value in Medtech · null in contracts
  • GYNION, LLCSimilar federal contract value in Medtech · null in contracts
  • SCIKON INNOVATION, INC.Similar federal contract value in Medtech · null in contracts

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .